Ono Pharmaceutical Co Ltd. has identified diacylglycerol kinase α (DGK-α, DGKA) and/or diacylglycerol kinase ζ (DGK-ζ, DGKZ) inhibitors reported to be useful for the treatment of cancer.

Neuron23 Inc. has synthesized leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer, neurodegeneration and Parkinson’s disease.

Eli Lilly & Co. has disclosed fibroblast growth factor receptor 3 (FGFR3) inhibitors reported to be useful for the treatment of cancer.

Exscientia plc has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, autoimmune disease, cancer, gout, inflammatory and neurological disorders, psoriasis and sickle cell disease.

Halda Therapeutics LLC has identified heterobifunctional compounds reported to be useful for the treatment of cancer.

Alterome Therapeutics Inc. has divulged RAC-α serine/threonine-protein kinase (AKT1; PKBα) (E17K mutant) inhibitors reported to be useful for the treatment of cancer.

Chiesi Farmaceutici SpA has synthesized heterocyclic derivatives acting as Janus kinase (JAK) inhibitors reported to be useful for the treatment of acute lung injury, asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

Tibet Haisco Pharmaceutical Co. Ltd. has disclosed integrin α4β7 (LPAM-1) and/or α4β1 (ITGA4; VLA-4) antagonists reported to be useful for the treatment of inflammatory disorders.

Dizal (Jiangsu) Pharmaceutical Co. Ltd. has described EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.

Nectin Therapeutics Ltd. has divulged antibody-drug conjugates (ADCs) comprising a humanized monoclonal antibody targeting poliovirus receptors (PVR; CD155) linked to a cytotoxic drug through a linker. They are reported to be useful for the treatment of cancer.